Phaseline

Companies › Marengo Therapeutics

Marengo Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STAR0602
Selective TCR-targeting bifunctional antibody-fusion molecule
TCRA, TCRBPhase 1Triple Negative Locally Advanced Non-resectable Breast Cancer; Advanced Solid TumorsJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06827613STAR0602Phase 1Triple Negative Locally Advanced Non-resectable Breast CancerOncologyJan 2027
NCT05592626STAR0602Phase 1Advanced Solid TumorsOncologySep 2027

Targets

TCRA (1) TCRB (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.